ArriVent BioPharma, Inc.

Direct answer

ArriVent BioPharma, Inc. is publicly traded on NASDAQ under the ticker AVBP.

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in...

Can you invest in ArriVent BioPharma, Inc.?

Yes. ArriVent BioPharma, Inc. is publicly traded on NASDAQ under the ticker AVBP.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for ArriVent BioPharma, Inc.

Detailed equity research is provided by MarketSnap.